Hi all. Has anyone heard about or tried Colostrinininis, a natural remedy for cognitive decline? It's marketed only through doctors offices here in the states under the name "CogniSure". It's made by a company called Metagenics who I'm told has a long and good reputation as a supplement manufacturer. The naturopath said this as well as some friends I have in the industry.
It's and isolated concentrate from the whole colostrum.

They are claiming it can halt the progress of AD. Any thoughts?

Hi,

Yes I have tried the the Australian version (Colostrinin) and Cognisure, the US version launched in the Usa in Oct 07.

My concentration has always been poor, and Cognisure has improved it a lot.

There is a lot of evidence which have been published in various journals to suggest that it halts the brain plaque, which is a big factor of AD.

The article below may help explain this better. I have posted other things about Cognisure/colostrinin under a message "Natures treatment"

kind regards, Rosie


Alzheimer's Disease

"New understandings in the treatment of AD"

Due to the failure of drugs having any significant impact on the condition, research into the treatment for Alzheimer's has been redirected to discovering possible treatments using colostrum extracts. ReGen Therapeutics has played a major role in this development and now is in the position after many years of research to release a product onto the market place which has been trademarked under the name of Colostrinin™. It has been under development as a neutraceutical treatment for 'the prevention of cognitive decline' in both humans and animals. In particular, diseases such as such as Alzheimer's and possibly the treatment of Parkinson's Disease.

From a general terminology point of view, Colostrinin is a proline-rich polypeptide complex produced from colostrum (a mammal's first milk) and is being developed as a nutraceutical for use in humans and animals for the prevention of early stage cognitive decline and is in advanced development as a treatment for Alzheimer's disease. Current research has been promising with Colostrinin™ showing efficacy in a 106 patient, placebo controlled trial conducted in mild/moderate Alzheimer's sufferers over 30 weeks. Results announced in April 2005 indicate that peptides within Colostrinin may have potential as a therapy for Parkinson's disease as well.

Colostrinin™ is ReGen's lead compound, which as mentioned is a proline-rich polypeptide complex produced from colostrum (a mammals' first milk after birth). In in vitro studies Colostrinin™ has been shown to prevent the aggregation of beta-amyloid and reduce it’s toxicity to cells. Beta-amyloid is the toxic peptide that is the main constituent of the characteristic plaques’ that form in the brains of people with Alzheimer’s disease and cause loss of cognitive function. Colostrinin™ has also been shown to protect cells from oxidative stress another of the pathologies implicated in Alzheimer’s disease. In in vivo studies Colostrinin™ has been shown to improve memory performance of aged rats in the Morris water maze test. Colostrinin has shown efficacy in a 106 patient, placebo controlled trial conducted in mild/moderate Alzheimer's sufferers over 30 weeks. Furthermore, Colostrinin™ and a synthetic homologue of Colostrinin™-derived peptide show neuroprotection in a cell line model of Parkinson's disease. An in vitro study has shown that pre-treatment with Colostrinin™ and a synthetic version of a peptide shown to occur naturally in Colostrinin™ can protect cells of the kind that are depleted in Parkinson's disease from damage by a chemical known to be selectively toxic to them. The initial data from this study suggests that Colostrinin™ and peptides within it may protect dopaminergic neurones against degeneration.

An in vitro study has shown that Colostrinin™ can cause precursor nerve cells to differentiate and proliferate. These findings suggest that Colostrinin™ treatment may control the expression of genes that are involved in the development, maintenance, and regeneration of neurons in the central nervous system, and thus may also explain the improvements observed in Alzheimer's patients with mild-to-moderate dementia during treatment with Colostrinin™.

A further in vitro study has shown that Colostrinin™ increases the lifespan of cells isolated from inbred mice predisposed to premature ageing and therefore, death. This study shows the impact of Colostrinin™ on the mitochondria of cells isolated from strains of senescence-prone (SAMP1) and senescence-resistant (SAMR1) mice. The data show that cells from SAMP1 mice produce more ROS, exhibit severe mitochondrial dysfunction, and have a decreased lifespan compared to the cells from SAMR1 mice. Addition of Colostrinin™ to SAMP1 cells significantly decreased ROS levels, normalized mitochondrial function and increased the lifespan to levels similar to those in SAMR1 cells. This is an exciting finding that may go toward explaining the cognitive benefits of Colostrinin™ seen in clinical studies. In vivo experiments are now ongoing to test if these effects are evident when SAMP1 and SAMR1 mice are given Colostrinin™ over their lifetime.

Having now achieved the production of Colostrinin™ at industrial scale ReGen announces that it is starting formal safety studies with Colostrinin™. While there have been no safety concerns associated with the use of Colostrinin™ in previously conducted safety or clinical studies, this is a key milestone for ReGen as these earlier studies used Colostrinin™ made with a small-scale process and using ovine rather than bovine colostrum. In parallel with the safety program, work continues to complete the incorporation of Good Manufacturing Practise (GMP) into the production process.

Last September ReGen presented preliminary evidence of an anti-ageing effect from Colostrinin™ at the 21st International Conference of Alzheimers Disease International taking place in Istanbul. Researchers saw that the product increased the lifespan of cells isolated from mice predisposed to premature ageing and therefore, death, when they tested its impact on the mitochondria of cells isolated from strains of senescence-prone (SAMP1) and senescence-resistant (SAMR1) mice.

While cells from SAMP1 mice produce more reactive oxygen species (ROS), exhibit severe mitochondrial dysfunction, and have a decreased lifespan compared to the cells from SAMR1 mice, adding Colostrinin significantly decreased ROS levels, normalized mitochondrial function and increased the lifespan to levels similar to those in SAMR1 cells.

Continuous low levels of oxidative damage to cells, caused by ROS, play a key role in age-associated neurodegenerative diseases such as Alzheimer's, Parkinson's disease and other disorders of the central nervous system.

Conclusion:

Based on current research, Colostrinin has the potential as a treatment for Alzheimer’s disease, Parkinson's disease and other neurodegenerative disease conditions.

Cognisure good for Pet Ad too:


Colostrinin™ Study Results

11/02/2008

ReGen Therapeutics Plc ('ReGen'or the 'Company') announces that its product Colostrinin™, which is currently marketed in the USA and Australia under the brand name CogniSure™, a nutritional supplement to 'support healthy brain aging and cognition in humans'* has recently been shown to be beneficial and well-tolerated in aging pet cats and dogs with signs of senility and/or cognitive dysfunction.

Open pilot studies, conducted by Cinque Ports Veterinary Associates, Hawkhurst, Kent, UK involved the daily dosing of aged cats and dogs with Colostrinin™ powder sprinkled into their food or drink.

To be eligible for the study, subject animals displayed acknowledged clinical signs of senility and/or cognitive dysfunction. Eighteen cats and twenty-two dogs, each resident in their normal domestic environment, received a daily dose of Colostrinin™ for four months. The clinical condition of each animal was assessed by a veterinary surgeon and the owner completed a questionnaire about aspects of the animal's behaviour at monthly intervals. Results were compared to individual base-line assessments, prior to treatment.

Summarising the study findings Nicholas Mills, Principal Investigator to the study said 'These results clearly show that Colostrinin™ can significantly reduce the symptoms of cognitive dysfunction in aged cats and dogs. That Colostrinin™ was effective was reinforced by the fact that when animals were assessed one month after completion of the study, and having had no Colostrinin™ for one month, most animals showed a worsened condition'.

The study showed Colostrinin™ to be well tolerated. With regard to specific benefits, a number of owners noted improvements in symptoms related to disorientation, sleep and grooming. A significant proportion of owners reported an increase in appetite, water consumption and an improvement in coat condition.

Percy Lomax, Chairman and Chief Executive Officer of ReGen said 'These results show a potential benefit for aging cats and dogs and we are entering into discussions with potential licensees. The full results are being written up with a view to publication in a peer-eviewed veterinary journal'

How do you go about getting cognisure?

If you enter Cognisure into Google, it will bring up various suppliers.

I have used the one below in the past

http://spinelife.stores.yahoo.net/co30tc.html

regards, Rosie

Thank you all for your info.

No problem...another intersting link showing the before and after effect on brain plaque...

https://www.alzheimersupdate.info/CogniSure_detail.html

Hello all

Two new articles from 2005 which says Colostrinin (Cognisure) can reduce brain plaque and increase cell life.


Peptide nutraceutical reduces build-up of Alzheimer's plaques

30-Jun-2005 - A mixture of peptides derived from colostrum could help slow the progression of Alzheimer's disease by reducing the build-up of beta amyloid, a toxic protein that accumulates in the brains of Alzheimer's sufferers, reports Dominique Patton.

ReGen Therapeutics, a UK firm focused on creating drugs for Alzheimer's disease, gained the rights to the polypeptide product Colostrinin in the late 1980s from a Polish research institute.
It initially sought to develop the compound as a pharmaceutical but over the last two years has changed its focus to the nutraceutical market and is now in discussions with partners to market Colostrinin for the 'maintenance of healthy mental function'.

The supplement could be available in North America by next year, according to ReGen chairman and chief executive Percy Lomax.

A double-blind, placebo-controlled trial on 106 people with mild to moderate Alzheimer's disease, published last year, found that after 15 weeks of taking the product in tablet form, around 40 per cent of the patients were stabilised or had an improved overall response in tests on cognitive function.

The greatest effects were seen in earlier stages of the disease and no serious adverse events were observed during the trial.

The new research, published online in the peer-reviewed journal Neuropeptides on 9 May, reveals a possible mechanism for this effect. Colostrinin appears to prevent the aggregation of beta-amyloid peptide Abeta (1-40) in vitro, dissolving the dense fibres that form in the brain over time.

Dr Marian Kruzel, the company's chief scientific consultant and a co-author of the publication, said: "There is consensus in the scientific community that the production and accumulation of beta amyloid aggregates is central to the pathogenesis of Alzheimer's disease. We believe that this data provides the molecular basis for explaining the beneficial effect of Colostrinin in patients with mild and moderate Alzheimer's disease, which was reported by ReGen last year.

"
She added that the study confirms preliminary findings reported at the Alzheimer's Europe conference in Prague last May. They showed that Colostrinin even at very low concentrations can protect nerve cells from the toxic effect of beta amyloid fibrils.

The company is doing further research to clarify the biochemical basis of this action.



28-Sep-2005 - UK-based ReGen Therapeutics has preliminary evidence of an anti-ageing effect from its nutraceutical Colostrinin.

The colostrum-based product increased the lifespan of cells isolated from mice predisposed to premature ageing and therefore, death, researchers will report today at the 21st International Conference of Alzheimer's Disease International taking place in Istanbul.
They tested the impact of Colostrinin on the mitochondria of cells isolated from strains of senescence-prone (SAMP1) and senescence-resistant (SAMR1) mice.

While cells from SAMP1 mice produce more reactive oxygen species (ROS), exhibit severe mitochondrial dysfunction, and have a decreased lifespan compared to the cells from SAMR1 mice, adding Colostrinin significantly decreased ROS levels, normalized mitochondrial function and increased the lifespan to levels similar to those in SAMR1 cells.

"This is an exciting finding that may go toward explaining the cognitive benefits of Colostrinin seen in clinical studies," said the study's lead investigator, Dr Istvan Boldogh based at University of TexasMedical Branch, Galveston.

"In-vivo experiments are nowongoing to test if these effects are evident when SAMP1 and SAMR1 miceare given Colostrinin over their lifetime," he added.

Continuous low levels of oxidative damage to cells, caused by ROS, play a key role in age-associatedneurodegenerative diseases such as Alzheimer's, Parkinson's disease andother disorders of the central nervous system.

A clinical trial on the ReGen product - a mixture of peptides isolated from colostrum - showed an improvement in cognitive function in Alzheimer's patients.

A new article has been published in the latest Journal of Alzheimers Disease regarding Colostrinin (Cognisure)

You can buy this currently as a nutracetical, but they are developing a pharmaceutical version also.

-----------------------------------------

http://iospress.metapress.com/content/w07224q30717g012/?p=90d19f13669c41c286c9ff4b92315276&pi=1

Scientific Review published

25/04/2008

ReGen Therapeutics Plc ('ReGen' or the 'Company') announces that a full review of the extensive science behind its product ColostrininTM, has been today published online in the Journal of Alzheimer's Disease.* This review states that when given orally ColostrininTM has been shown to have a stabilising effect on cognitive functions in improving the conditions of patients suffering from mild to moderate Alzheimer's disease. This review concludes that, whilst further extensive studies are required to understand the mechanism by which ColostrininTM exerts its biological effects, ColostrininTM clearly has potential benefit in the prevention and treatment of neurodegenerative disorders.

ColostrininTM is marketed in North America and Australia under the brand name CogniSureTM as a nutritional supplement to 'support healthy brain aging and cognition' in humans** and is available through the professional channel of healthcare practitioners such as chiropractors and doctors. The product is expected to be launched in the European Union in 2008.

Summarising this publication Dr. Marian Kruzel*** a co-author of the report said:

'This is a most comprehensive review regarding the potential utility of ColostrininTM in neurodegenerative disorders. It includes research into the novel mechanisms of action involved in neuroprotection and clearly presents Colostrinin'sTM biodiversity. This is the whole story of the potential of Colostrinin'sTM proactive function in age-associated mental capacity.'

Percy Lomax, Chairman and Chief Executive Officer of ReGen said:

'This review paper demonstrates the hard scientific evidence concerning the activity of ColostrininTM. This amount of scientific evidence is unusual for a nutraceutical and should support the further development of our marketing platform. We would also stress that this paper adds weight to our view of the likely potential of our ColostrininTM derived peptide programme to produce a pharmaceutical product that will be used in the treatment of neurodegenerative diseases.'

Thanks Rosie!

Rosie, thanks so MUCH for posting this information and the links... This sounds promising!

Interesting someone had the inclination to share this by doing a double blind study!


[quote]A double-blind, placebo-controlled trial on 106 people with mild to moderate Alzheimer's disease, published last year, found that after 15 weeks of taking the product in tablet form, around 40 per cent of the patients were stabilised or had an improved overall response in tests on cognitive function.[/quote]

Hi everyone,

News out today regardiing further reseach showing that Colostrinin/Cognisure helps with AD. You can already buy Cognisure as a nutraceutical, but this gives further hope to devloping a pharmaceutcal version too.



--------------------------------------------
New Study published

26/06/2008

Study showing that ReGen's Colostrinin™ protects hippocampal cells against beta-amyloid and oxidative stress is to be presented at the FENS Forum 2008

ReGen Therapeutics Plc ('ReGen' or 'the Company') announces the publication of a new study showing that ReGen's Colostrinin™ protects hippocampal cells against beta-amyloid and oxidative stress. The research, which has been performed by ReGen's collaborators at the Open University, Milton Keynes, United Kingdom is to be presented as a poster at the FENS Forum 2008*, Geneva on 16 July 2008.

It has previously been shown that Colostrinin™ can prevent beta-amyloid induced impairment of learning in newly hatched chicks [1] and can protect standardised laboratory neurological cells against beta-amyloid induced toxicity and oxidative stress induced damage [2]. However, the research presented at the FENS Forum is the first study to show these effects on isolated hippocampal cells.

Commenting on the study, Professor Mike Stewart the senior investigator and scientific advisor to ReGen said

'These findings are very significant as the hippocampus is one of the key brain areas known to be affected in neurodegenerative diseases such as Alzheimer's disease. It is of particular importance to note that Colostrinin™ can directly protect these neurons that have such an important role in cognition and memory'.

Percy Lomax, Chairman and Chief Executive of ReGen said

'This research gives us further confidence in promoting Colostrinin™/CogniSure™ as a nutraceutical for healthy brain ageing. Longer term it adds to our belief that our peptide programme may be able to produce a pharmaceutical product with utility in Alzheimer's disease and other similar neurological disease conditions'.

A copy of the full abstract is available at:

http://fens2008.neurosciences.asso.fr/pages/posters_sessions.html

(Poster session 7 - Wednesday, July 16, 09:30-13:00, Section P217 - C: Alzheimer's 4). Froud K., Saffrey M. J., Stewart M. G., Banks D. & Wardhaugh T.

* The FENS Forum is the premier European Neuroscience meeting of 2008

1. Boldogh, I, Kruzel, M. L Journal of Alzheimer's Disease 13 (2008) 303-321
2. Banks D, Stewart M. G. Soc Neurosci Abstr proceedings (2006) 674.5.

When I first noticed this thread I didn't read all of it and I went around to some stores to see if they had it. No one had it, now I realize it's something you have to order. Does a doctor have to prescribe it.

Is the cosmagenisis or Colostrinin that was mentioned earlier in this thread the same thing?

Thanks, Felicia

Check the links for yourself, Felicia - it isn't the same thing and this exact same message has been posted at other forums. It's called spamming.

Thanks, I kept going up and down so much I actually missed the link from whatagal!

Felicia

Hi Everyone,

Just to confirm what others have said, the product 'whatagal' mentioned is nothing to do with Cognisure/Colostrinin.

I have only found Cognisure on line from suppliers in the United States or Australia . I have used a link from my post on April 3rd, but you can "google" Cognisure and choose from many different suppliers.

The latest reseach findings on Cognisure/colostrinin says that it helps the hippocampus. I wasn't sure how significant this was so I looked up hippocampus and found the following:

"The hippocampus is a part of the forebrain, located in the medial temporal lobe. It belongs to the limbic system and plays major roles in short term memory and spatial navigation...In Alzheimer's disease, the hippocampus is one of the first regions of the brain to suffer damage; memory problems and disorientation appear among the first symptoms"

Of course, I encourage you not to just rely on my reseach but investigate yourself too. Although I am happy to post what I find, as I know its not easy to find spare time "surfing" these days!

kind regards

TTT

Colostrinin/Cognisure can apparently help reduce Tau AND brain plaque - both associated with AD. This will be explained at an ad convention- details below

------------------------------------------

Alzheimer's Conference on September 17th

Professor Marian Kruzel, the Company's Chief Scientific Advisor will be presenting a poster reviewing how Colostrinin* achieves its clinical effect at the first Clinical Trials in Alzheimer's Disease Conference, to be held in Montpellier, France, September 17th 2008.

Summarising the contents of his poster, Professor Kruzel said:

"In this presentation I will explain how such a low dose of Colostrinin* can produce significant medical benefits in AD patients. I will focus on our findings from recent genomic microarray work, which shows that Colostrinin* can favourably modulate the expression of several molecules involved in the pathology of Alzheimer's disease (upregulation of bleomycin hydrolase, downregulation of APP and effect on Tau phosphorylation). This enables the body's own multiple responses to reduce neuronal pathology and achieve homeostasis. The effect on Tau is said to be the reason for the response witnessed by the patients taking the drug Rember*. This data suggests that Colostrinin*, may be one of the first compounds with the potential to impact both Tau tangles and beta amyloid plaques, the two key pathologies of Alzheimer's disease."

http://www.find-health-articles.com/rec_pub_16473531-enhancement-long-term-memory-retention-colostrinin-day-old-chicks.htm

http://www.if-pan.krakow.pl/~popikp/download/9843_popik_pbb_1999.pdf

Experiments showing how COlostrinin (Cognisure) helps memeory in Rats and Chicks

My mother has had continuing memory decline for the past three years,last May i took her to the local doctors surgery to have a memory test to find out if she had a serious problem or not,she did not do very well with the test and her doctor then asked to take blood tests and take a brain scan,on completion of these she was diagnosed with mild AD,a few weeks later she started taking the drug Galatamine,it took several weeks to kick in and there was some side effects with stomach problems but these were on the mild side.
For about 6 month's her memory seemed to improve,but she was still having problems with short term memory loss,it was about this time that i started reading up about the cognisure product which had just been released in the united states,at first i decided not to purchase the product that was until my mothers memory started to deteriorate once more,she started becoming delusional believing that another person lived in her house with my dad,she would also start to muddle up my name with my brothers name.So i took the plunge and ordered the cognisure,from reading the information on the clinical trials which took place with this drug it would take about 2-3 months to start working,after about 7 weeks i noticed that my mother would start remembering things which she had been doing during the day and explaining to me in detail conversations she had been having with her friends.From reading this forum about cinnamon i also started her on this about 8 weeks after starting Cognisure.
It's now been 11 months of taking Galatamine,4 months Cognisure and 2 months cinnamon,her memory has and continues to show improvement,she has no more delusional moments,her appearance and mood have become much more uplifting.Two weeks ago the mental health nurse visited her at home to test her memory,she scored an amazing 29/30 on the mmse test.I believe that the Cognisure has been a big help to her memory.

Wow Ian R, that's wonderful...We are also into supplements.
Can you please tell me the brand and dosage of each that your mom is taking? My DH is doing fairly well, we do not use the Cognisure. I'm impressed with your mom's MMSE!
What was the first score? Thanks IanR


Jeanne

,

Wow Ian R, that's wonderful...We are also into supplements.
Can you please tell me the brand and dosage of each that your mom is taking? My DH is doing fairly well, we do not use the Cognisure. I'm impressed with your mom's MMSE!
What was the first score? Thanks IanR


Hi jdm!
My mother takes one capsule of Galatamine 24mg per day,2000mg of Cinnamon,solgar is company which makes this and it is the Cassia variety.Purchased online from iherb.com
And in last 2 weeks she has also been taking Turemic 1500mg per day.
As for Cognisure she has a regime where one tablet every other day for 3 weeks,then a break of 2 weeks without taking any.

IanR

I checked the ingredients of Cognisure and it contains lactose. My DH is lactose intolerant but I may give it to him anyway along with the lactaid enzyme. It sounds like a great product and the benefits may outweigh the side effects. It sounds as though your mom is on a good plan but most importantly, she has a loving son.

Thank you for responding.

Jeanne

Good to hear that Cognisure is working!

An English University has published the below about Colostrinin/Cognisure recently, giving further proof of its worth in AD.


Expert Opin Pharmacother. 2008 Oct;9(14):2553-9.

Colostrinin(): a naturally occurring compound derived from mammalian colostrum with efficacy in treatment of neurodegenerative diseases, including Alzheimer's.Stewart MG.
The Open University, Laboratory of Functional Neurocytology, Department of Life Sciences, Milton Keynes, MK7 6AA, UK +44 1908 653448 ; +44 1908 654167 ; m.g.stewart@open.ac.uk.

Neurodegenerative illnesses such as Alzheimer's disease and their debilitating effects pose a major problem as their incidence increases. Although clinical management of neurodegenerative diseases usually involves symptomatic treatment, Colostrinin() (CLN), which has efficacy in counteracting neural degradation and in stimulating neural growth, might prove to be a more effective means to deal with the causes of Alzheimer's and other neurodegenerative diseases. Evidence for the clinical efficacy of CLN is discussed and recent data examined showing the remarkable ability of CLN to reduce oxidative stress, prevent beta-amyloid aggregation and prolong the lifespan in a laboratory model of premature ageing. An increasingly important application for CLN has been as a nutraceutical product for use in the early stages of cognitive decline in humans, with licensed use in North America and Australia, and now in Europe. It might also be of considerable utility as a veterinary nutraceutical for companion animals.

TTT

Colostrinin (cln) is ok for lactose intolerant people (please see below)

---------------------------------------------
CLN is suitable for lactose intolerant people as the amount in each tablet is very, very low. As a product derived from milk products however it is legally required that 'contains milk proteins' is stated on the box in most countries. Consequently it is not possible to put that it is OK for lactose intolerant people on the box - we can only spread this message by word of mouth etc.

Hopefully (!) my bro has started on the Cognisure today. I'll keep you all posted. Also, hopefully back on the Cinnamon too.

All the very best with your Brother, DebZ. I hope you see some improvements

I have bought Colostrinin from Australia when it first launched in July 07 & then the USA in Oct 07 as Cognisure.

Apparently you can now get it in parts of Europe under the name of "Cognase". I understand that it is still Colostrinin (PRP).

There is an interesting Q & A about the product Cognase/Cognisure/Colostrinin which I have posted below.

I have been told by the Cypriot company that they will sell it in Euros on line in the future. When they do I will post the link. Those, like me, in the UK will save a lot in postage.

It will be ideal when they get it in the shops over here. Anyone else been able to get it in the shops where you live? I have asked in Health stores, and I guess the more you ask, the better the chance of them stocking it!

All the very best.

R
----------------------------------------------
Q. What is Cognase™?

A. Cognase™ is an all-natural clinically researched proline-rich polypeptide (PRP) complex that supports healthy brain aging and the maintenance of normal mental function.

Q. What is a PRP complex (also known as Colostrinin™)?

A. A PRP complex is a colostrum-derived extract of proline-rich peptides that consists of less than 0.1% total colostrum. Through a unique patented extraction process, this naturally occurring protein from bovine (i.e. cows’) colostrum has shown exceptional qualities in protecting brain cells and promoting healthy brain aging.

Q. Is this product sold under different names?

A. This product is sold in Cyprus under the trade name Cognase™. In other countries, such as the United States, Canada and Mexico, it is sold as CogniSure™. In Australasia it is sold as Colostrinin™. Essentially, all these products contain the same PRP complex extracted using the same patented technology.

Q. Who might benefit by taking Cognase™?

A. Cognase™ may be beneficial for adults of all ages who are concerned about healthy brain aging. Obviously those most at risk of developing age-associated memory impairment and dementia are the elderly, for whom supporting the brain’s aging process and ensuring normal mental function is of paramount importance. However, due to its remarkable protective and antioxidant properties, Cognase™ can offer even healthy younger adults (younger than 65) the opportunity to take action early to support the brain and help protect it from diseases like dementia.

Q. Is Cognase™ safe?

A. The source of Cognase™’s PRP complex is bovine colostrum made by the mother’s body to boost her newborn’s immune and neurological systems. Our PRP complex has been studied extensively over the last several decades. The safety and lack of toxicity of Cognase™ is well documented and supported by both animal and human studies. However, people with dairy sensitivities should consult their doctor prior to taking Cognase™.

Q. I already take colostrum. Am I getting enough Colostrinin™ (i.e. PRP complex)?

A. No. The amounts of PRP complex in colostrum are minute. Using a patented technology, Cognase™’s PRP complex is separated from whole colostrum, releasing the full biological activity of its unique peptides and making it much more bioactive and bioavailable than plain colostrum.

Q. How is Colostrinin™ different from colostrum?

A. Unlike whole colostrum, which has immune and growth supporting properties, Cognase™’s PRP complex (Colostrinin™) specifically influences healthy brain function and is designed to exclude allergens commonly associated with milk products.

Q. If I am sensitive to dairy products, can I still take Cognase™?

A. Yes, unless you are particularly sensitive. Cognase™ is free of intact proteins (e.g. casein) associated with milk allergies, as well as lipids, minerals, and most carbohydrates (lactose). It is important to remember that food allergies and sensitivities can be complex. Cognase™’s PRP complex may not be appropriate for individuals with severe milk allergies.

Q. Why should I take Cognase™ when there are so many other brain foods and neuroprotective agents available?

A. Cognase™’s PRP complex is unique, natural and safe. It has been studied extensively and its safety and lack of toxicity are well-documented and supported by both animal and human studies. Its powerful neuroprotective properties and health benefits have been established by many years of research, making it suitable for adults wishing to use a natural product to support the healthy aging of their brain.

Q. How does Cognase™ compare with Ginkgo biloba in terms of neuroprotection?

A. Ginkgo biloba, extracted from the leaves of the Maidenhair tree, targets blood circulation. Ginkgo is primarily used to increase the blood supply to the brain by dilating blood vessels, reducing blood viscosity, modifying acetylcholine and reducing the density of free radicals (oxidative stress). Ginkgo’s influence on acetylcholine can make this herb beneficial for older individuals experiencing declining acetylcholine levels. In contrast, Cognase™’s PRP complex does not directly influence acetylcholine. Instead, it protects the structures responsible for the synthesis of acetylcholine and other neurotransmitters. Also, Ginkgo may have some undesirable side effects, whereas Cognase™ has shown no serious adverse effects at all.

Q. Can Cognase™ be taken with Ginkgo biloba?

A. Cognase™ can be taken along with Ginkgo biloba, especially when an individual is showing the early signs of age-related mild cognitive decline, such as forgetfulness or minor lapses in memory. These mental processes, including critical thinking, concentration, and speech, are dependent on continued neuroprotection. In younger individuals, Cognase™, taken with omega-3 fatty acids from high quality cold-water fish, together with multivitamins, may provide good neuroprotection.

Q. How long should I take Cognase™ in order to get the health benefits?

A. Clinically beneficial effects have been shown in as little as 100 mcg of PRP complex taken every other day. This specific dosing regimen was established as effective in clinical research. No other natural agent has demonstrated these benefits in such minimal amounts, making PRP complex a safe, potent, and cost-effective neuroprotective agent.

http://www.healthybrainaging.com/index.html

At last, one year after the USA launch you can now buy Cognisure/Colostrinin in Euros on line (as Cognase).

The website is above. I have ordered 1 unit which cost me 33 Euros. I understand from the site that postage is free if you order 3 or more.

This should be cheaper for those who are in Europe. If you are not, then the website has some interesting information about colostrinin anyway.

all the best
R

TTT

Cognisure (Colostrinin or CLN) has been published in another magazine.

They have confirmed that Colostrinin/Cognisure can have an effect on Tau and Plaque. I am not aware of any other AD treatment that can do this...rember can only control one of them.

Good stuff, and you can buy it as a nutra..the pharma version may take until 2012 though, but it is being developed so I understand.

-------------------------------------------
4 December 2008

ReGen Therapeutics Plc <AIM:RGT, OTCQX:REGUY>

Full Results of Study Showing how ReGen's Colostrinin* achieves its

Clinical effect Published in Peer-reviewed Journal

ReGen Therapeutics Plc ("ReGen" or the "Company"), is pleased to announce that the full results of this genomic microarray study, which was first reported as part of ReGen's Interim Results statement issued on the 23rd September 2008, has now been published on-line ahead of availability in print by the peer-reviewed journal International Immunopharmacology.

We emphasise two key points of the article. Firstly, Colostrinin* can favourably modulate the expression of several molecules involved in the pathology of Alzheimer's disease - upregulation of bleomycin hydrolase, downregulation of APP and effect on Tau phosphorylation. Given that Alzheimer's is a complex disease, the multi-faceted action shown by Colostrinin* is significant. Secondly, Colostrinin* also modulates other molecules involved in biological pathways associated with other conditions such as obesity and allergy.

ReGen's Chairman and Chief Executive, Percy Lomax said:

"For a long time ReGen has had compelling experimental and clinical data that suggest Colostrinin* achieves its clinical effect and support our belief that it is one of the first compounds with the potential to impact both Tau tangles and beta amyloid plaques, the two key pathologies of Alzheimer's disease. Publication of the research will be a useful tool in the further commercialisation of the product".

The abstract of this study is reproduced below. The text of the full article (charged) is now available at: www.ncbi.nlm.nih.gov/pubmed/ by searching on the name of the first author.

Study Abstract:

Effects of Colostrinin on gene expression-transcriptomal network analysis.

Szaniszlo P, German P, Hajas G, Saenz DN, Woodberry MW, Kruzel ML, Boldogh I.

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States.

Colostrinin (CLN) is a uniform mixture of low-molecular weight proline-rich polypeptides isolated from the mother's first milk, colostrum. Exposure of cells to CLN decreases intracellular levels of reactive oxygen species by regulating glutathione metabolism and modulating activities of antioxidant enzymes and mitochondrial function. It also inhibits beta amyloid-induced apoptosis and induces neurite outgrowth of pheochromocytoma cells. Administration of CLN to Alzheimer's disease patients has resulted in a stabilizing effect on cognitive function. We analyzed CLN-induced gene expression changes using high-density oligonucleotide arrays and transcriptomal network analysis. We found that CLN elicited highly complex and multiphasic changes in the gene expression profile of treated cells. CLN treatment affected a total of 58 molecular networks, 27 of which contained at least 10 differentially expressed genes. Here we present CLN-modulated gene networks as potential underlying molecular mechanisms leading to the reported effects of CLN on cellular oxidative state, chemokine and cytokine production, and cell differentiation, as well as on pathological processes like allergy, asthma, Alzheimer's, and other neurological diseases. Based on our results, we also predict possible modulatory effects of CLN on adipocytokine gene networks that play a crucial role in the pathobiology of diabetes, cardiovascular disorders, obesity, and inflammation. Taken together, CLN-altered gene expression networks presented here provide the molecular basis for previously described biological phenomena and predict potential fields of application for CLN in the prevention and treatment of diseases.

Thanks Rosie. I've printed out your post (hope it's ok?!) and am sending it along to my bro in the hope that he'll continue with the Cognisure I ordered and sent out to him in Nevada.

Debz - Have you or your brother noticed any difference since he started taking it in October?

I am just searching around for alternatives since we took my mom off the aricept.

Leah - most unfortunately, he hasn't been given it according to the directions, i.e. he was getting it every day, instead of every other day for the three weeks, then off for two weeks. Soooo, I don't know what that is/was doing to him. I'm hoping now he's on the correct dosage - he's in Nevada with his second wife, I'm in upstate NY so I don't have control of what he's getting. Makes me crazy! I certainly will post here any kind of change that's noticed within the next month or so.

My opinion is to try everything and anything that might help. The Cognisure, particularly in view of Rosie's last posting above, is certainly something I feel is worth a try.

Hello everyone,

No problem in printing off my posts Debz...spread the word. From my experience and what I have researched in regards to Nuraceuticals, stuff like Vitiman E and Ginko Biloba does not work.

Ginko for example only increase the blood flow round the brain and may only be a temporary fix, like if you drank a cup of coffee, if it works at all. Much new research suggests Ginko doesn't work in AD.

Colostrinin, or Cognisure is quite an exciting discovery and is having new reseach posted about it all the time.

My Doctor explained that something like Aricept just treats the sypmtoms of AD, it doesn't actually halt the disease itself. The same way paracetimal may treat the sypmtoms of a cold...it doesn't actually cure it.

From the reseach on Colostrinin/Cognisure it treats more than just one part of the disease, ie it deals with the Brain plaque AND the Tau. I am sure that Aricept does not do this, and you may have heard of rember which only controls one of these two. I am not aware of any AD product in trial or on sale that can treat so many areas of AD.

I don't know for sure if Cognisure can reverse servere AD...the trial was for mild to moderate, but the nutraceutical version should at least help prevent further decline.

I have found it helpful for forgetfulness over the year and a bit I have been taking it. The results wern't immediate, but come with time. I guess it may depend from person to person. I also found it helpd with anixety and depression...a bit of chill pill. Others I know have also mentioned Cognisure helping with their 'hay fever', and the latest reaseach does say about treating allergies.

I have tried the capsules and the chocolate tablets. Slowly chewing on the chocolate is best for me, or opening the capsules and pour into a drink if you have those. Apparently it gets into the 'system' as soon as it is left in the mouth. So it is good just to let it slowly disolve in the mouth and enjoy the chocolate!

p.s I have been taking it most days, and not bothering with the break....it's natural and so it seems to have no adverse effects. You may want to ask professional advice on this though.

I hope this helps!

All the very best

where to get this? is it available now? i need to research.

Hi - You can buy Cognisure/Colostrinin as a Nutraceutical. It was launched in the USA last last year and Europe a couple of months ago (as Cognase)

If you enter Cognisure into Google, it will bring up various suppliers.

I have used the one below in the past which is based in the USA (spinelife). I have posted a second US supplier below which has an interesting article on the brain plaque.

http://spinelife.stores.yahoo.net/co30tc.html

https://www.alzheimersupdate.info/CogniSure_detail.html

However, as I live in England, they now stock it in Europe which is the link below which sells in Euros. It has interesting info about the product too.

http://www.healthybrainaging.com/index.html

Hope this helps!

Rosie - Is this something that you are taking yourself only or are you giving it to anyone else too?

I like the fact that it's chewable. There are so many vitamins on the market that I can't give my mom because she won't swallow large pills without choking on them so she tries to chew even cel caps.

My parents are coming over today so I'm going to let my dad read all this.

LeahS

Just me taking it. It's very easy to take - I understand that it is more beneficial if you just let it dissolve in your mouth - the US verion is chocolate & so is the European version, so it is very pleasent to take.

The size of the pill isn't big either, so it should be ideal hopefully.

all the very best

https://www.metagenics.com.au/shop/index.cfm?fuseaction=item&id=793&i=1&CFID=20202584&CFTOKEN=98712179

Hi...above is a link for those who might live in Aus and NZ, although you can get the Australian version overseas. I have used this type before the chocolate version came out in the States and Europe. It is in a capsule version and you can sprinkle the contents in food or drink for best effect. This may be better for those who find it hard to digest tablets.

kind regards

Hello Rosie 56, Wow I think you found something very important. More later.

Rosie, I've just seen this thread and I'm wondering if you could use CogniSure while taking Aricept? It sounds like a great product. Thanks!

Hello whitney.

There is nothing on the box or in the instructions of the Cognisure/Colostrinin I have bought to say it contradicts other medicine.

Of course, I don't know for definate, but what I can say is, Cognisure (or Colostrinin, Cognase depending on where you buy it) is 100% NATRUAL, ie: it is a nutraceutical, like Ginko or Colostrum. In fact Colostrinin is extracted from Colostrum. So effectively its like a food suppliment.

They warn you of side effects, but there are none because its natural. There have been no side effects in the trials.

If you do try it, go for the chocolate tablets that you can dissolve in your mouth.

Dissolve for as long as you can, as it gets into your system better this way.

I hope this helps. It may be worth asking one of the suppliers. If I find out any more I will let you know.

all the best

Thank you, Rosie!

No problem, whitney...I got an email back today from the manufacturer which says.."There is no known interaction." when I asked about the usage of Cognisure and Aricept. So it looks like it will be worth a try!

Best of luck,

R

http://www.kenes.com/adpd2009/posters/Abstract250.htm
and
http://www.kenes.com/adpd2009/posters/Abstract977.htm

Just to mention Colostrinin is getting a mention at the next major Alzheimer's conference. Word is getting out there re what cognisure can do to help in ad!

http://www.cognisure.eu/

Cognisure now launched in Poland for those of you who may live there. Still waiting for it to come to Britain!

How can a polypeptide taken orally possibly do anything? It would be digested down to its constituent amino acids before it ever reached the bloodstream. True the amino acid proline abundant in Cognisure has been shown to assist protein folding, but the amount of polypeptide, 100 micrograms per tablet, is far too small to have any effect by this route. You can buy generic free proline for a microfraction of what you would pay to get it from Cognisure.

Hi remig,

I have been told to suck the chocolate tabs slowly as much of the benefit of Colostrinin (Cognisure) is apparently via the mouth and some how works through to the lymphatic system. Apparently it works better this way, rather than straight to the stomach as the stomach acid may take some effect away.

To be honest I don't fully understand all of the scientific stuff, but there is a TON of reseach on this product showing its effectiveness in animals and humans. More than any other nutraceutical. Some are in major AD magazines, eg Journal of Alzheimers disease.

A pharmaceutical version is apparently being developed, but this is going to be a synthetic version.

best wishes

R